TNF antagonists including infliximab and adalimumab have been reported to reduce the frequency of AAU.32–34 A meta-analysis estimated the frequency of uveitis in patients with AS who were treated with infliximab and etanercept therapies and concluded that infliximab was more effective than etanercept.35 When Etanercept was indirectly compared to other monoclonal TNF antagonists, it showed higher AU flare rates. Here, TNF is linked to uveitis.